Hims & Hers' stock fell 13% after reporting a Q1 net loss of $92M, weak earnings guidance, and ongoing controversy over weight loss drug sales, despite a deal with Novo Nordisk.
Hims & Hers shares fell 15.5% in premarket trading after the company reported a $92 million first-quarter loss and provided earnings guidance that disappointed investors.
Hims & Hers shares fell in premarket trading after the company reported a $92 million first-quarter net loss and issued guidance that Citi described as mixed. Investors also focused on the firm's transition away from compounded GLP-1 sales.
Hilary Coles, co-founder of Hims & Hers, has launched Golden Child, a premium dog food company, with $37 million in funding. The company offers a fresh frozen meal system starting at $3/day and a $19.95 shelf-stable liquid topper called 'drizzle.' Backed by Redpoint Ventures and Atomic Labs, the company claims to have identified gaps in the $7 billion pet food market through analysis of 11,000 customer reviews.
Hillary Coles, co-founder of Hims & Hers, has launched Golden Child, a premium fresh dog food company backed by $37 million in funding. The company offers fresh frozen meals starting at $3/day and a $19.95 shelf-stable 'drizzle' topper. Redpoint Ventures led the seed and Series A rounds with participation from Atomic Labs and A-Star. The startup employs 12 people including veterinary nutritionists and a chef.
Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
